Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

829
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
829
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same author

A novel US-based grading system for disease severity in sickle cell disease: the Sickle Cell Outcome Grading System (SCOGS).

The Lancet. Haematology·2026
Same author

Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease.

American journal of hematology·2026
Same author

Acute pain in pediatric patients with SCD without chronic pain is associated with elevated VCAM-1 and P-selectin adhesion.

Blood vessels, thrombosis & hemostasis·2026
Same author

Cortical Thickness Associated with the Degree of Anemia in Children with Sickle Cell Disease.

AJNR. American journal of neuroradiology·2025
Same author

National Alliance of Sickle Cell Centers Consensus Recommendations on Sickle Cell Disease Health Maintenance: A Consensus Statement.

JAMA network open·2025

Related Experiment Video

Updated: Jan 9, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K

Optimizing the right time to start sickle cell therapies.

Olufunke Y Martin1, Seethal A Jacob2,3

  • 1University of Texas Southwestern Medical Center, Division of Pediatric Hematology-Oncology, Children's Medical Center, Center for Cancer and Blood Disorders, Dallas, TX.

Hematology. American Society of Hematology. Education Program
|December 5, 2025
PubMed
Summary
This summary is machine-generated.

Optimizing sickle cell disease (SCD) treatment involves earlier, personalized interventions based on genetic and clinical factors. A proactive approach considering evolving therapies improves quality of life and survival for SCD patients.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.3K

Related Experiment Videos

Last Updated: Jan 9, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.3K

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Sickle cell disease (SCD) is a complex genetic disorder causing hemolysis and vaso-occlusion with diverse complications.
  • Newborn screening allows early SCD identification, but optimal timing for disease-modifying therapies (DMTs) is debated.

Purpose of the Study:

  • To review how genetic, clinical, and phenotypic factors influence the timing of DMT initiation in SCD.
  • To emphasize the evolving trend towards earlier and personalized SCD treatment strategies.

Main Methods:

  • Literature review of genetic and clinical risk factors impacting SCD treatment timing.
  • Analysis of current and emerging DMTs, including hydroxyurea, L-glutamine, crizanlizumab, voxelotor, stem cell transplantation, and gene therapies.

Main Results:

  • Early hydroxyurea initiation is supported for severe SCD genotypes but faces underutilization.
  • A growing number of therapies exist, necessitating individualized treatment decisions.
  • Phenotypic variability and risk stratification are key to optimizing intervention timing.

Conclusions:

  • A shift from reactive to proactive care models is needed for SCD management.
  • Multiagent approaches and biomarker-driven strategies may enhance outcomes.
  • Optimizing DMT timing improves quality of life and long-term survival in SCD.